Vestibular Rehabilitation with Intratympanic Drug Therapy in Meniere's Disease
DOI:
https://doi.org/10.51253/pafmj.v72i4.8696Keywords:
Dexamethasone, Gentamicin, IntratympanicAbstract
Objective: To evaluate vertigo control and auditory rescue in patients with Meniere's disease treated with intratympanic Gentamicin and Dexamethasone.
Study Design: Randomized Control Trial (Clinical Trials. gov Identifier: NCT05355610).
Place and Duration of Study: ENT Departments CMH Quetta and Benazir Bhutto Hospital Rawalpindi Pakistan from Apr 2020 to Mar 2022.
Methodology: Ninety-three cases of unilateral Meniere's disease meeting the inclusion criteria were treated with intratym-panic Gentamicin and Dexamethasone. Pre and post-treatment vertigo was assessed on Vestibular Deficit Index. Speech discrimination scores for auditory impact were also recorded pre and post-treatment.
Results: In the Ninety-three treated cases, there was a statistically significant improvement in the Vestibular Deficit Index (with a p-value of 0.001). Although all patients had a reduced speech discrimination score, it was not statistically significant (p value=0.08).
Conclusion: Control of vestibular symptoms can be achieved with intratympanic Gentamicin, and at the same time, the auditory system can be rescued with Dexamethasone.